Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 52,154 | -33,361 | 57,138 | -2,985 | 629,302 |
| Depreciation Amortization | 35,489 | 52,120 | 67,749 | 52,522 | 63,445 |
| Income taxes - deferred | 11,696 | 20,723 | -8,618 | -19,053 | 74,829 |
| Accounts receivable | -2,601 | 55,319 | -28,616 | -26,061 | 25,463 |
| Other Working Capital | -34,402 | 65,677 | -57,004 | -11,673 | -7,628 |
| Other Operating Activity | -12,759 | -22,628 | 48,149 | 61,836 | -814,747 |
| Operating Cash Flow | $49,577 | $137,850 | $78,798 | $54,586 | $-29,336 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 67,403 | 183,165 | 40,010 | 616,171 | -325,817 |
| PPE Investments | -3,521 | -17,923 | -8,761 | -4,458 | -2,553 |
| Net Acquisitions | -10,405 | N/A | N/A | -382,823 | 800,957 |
| Purchase Of Investment | -15,249 | -750 | N/A | -500 | -1,000 |
| Purchase Sale Intangibles | -49,910 | 92 | 494 | 1,358 | N/A |
| Other Investing Activity | -49,910 | -868 | -726 | 3,258 | -4,669 |
| Investing Cash Flow | $-11,682 | $163,624 | $30,523 | $231,648 | $466,918 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 202 | 18,938 | N/A | 12,401 |
| Debt Repayment | -76,854 | -260,949 | -155,760 | -222,209 | -39,724 |
| Common Stock Issued | 22,448 | 3,232 | 33,763 | 3,017 | 2,997 |
| Common Stock Repurchased | N/A | N/A | -18,446 | -77,998 | -453,428 |
| Other Financing Activity | -5,541 | -18,475 | -16,256 | -13,355 | -7,418 |
| Financing Cash Flow | $-59,947 | $-275,990 | $-137,761 | $-310,545 | $-485,172 |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | 83 |
| Beginning Cash Position | 45,006 | 19,522 | 47,962 | 72,273 | 119,780 |
| End Cash Position | 22,954 | 45,006 | 19,522 | 47,962 | 72,273 |
| Net Cash Flow | $-22,052 | $25,484 | $-28,440 | $-24,311 | $-47,507 |
| Free Cash Flow | |||||
| Operating Cash Flow | 49,577 | 137,850 | 78,798 | 54,586 | -29,336 |
| Capital Expenditure | -3,521 | -17,923 | -8,761 | -4,458 | -2,553 |
| Free Cash Flow | 46,056 | 119,927 | 70,037 | 50,128 | -31,889 |